Research Article

Construction and Comprehensive Analyses of a Competing Endogenous RNA Network in Tumor-Node-Metastasis Stage I Hepatocellular Carcinoma

Xuefeng Gu,1 Hongbo Li,2 Ling Sha,3 and Wei Zhao1

1Department of Liver Disease, The Second Hospital of Nanjing, Medical School, Southeast University, Nanjing 210003, China
2Department of Hepatology, Infectious Diseases Hospital Affiliated with Soochow University, Suzhou 215000, China
3Department of Neurology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China

Correspondence should be addressed to Wei Zhao; weizhaoseu@163.com

Received 26 October 2019; Revised 14 December 2019; Accepted 26 December 2019; Published 11 February 2020

Abstract

Long noncoding RNAs (lncRNAs) can function as competing endogenous RNAs (ceRNAs) and interact with microRNAs (miRNAs) to regulate target gene expression, which can greatly influence tumor development and progression. Different tumor-node-metastasis (TNM) stages of hepatocellular carcinoma (HCC) defined by the American Joint Committee on Cancer (AJCC) have different clinical results. Our purpose was to comprehensively analyze differentially expressed (DE) lncRNAs, miRNAs, and mRNAs in stage I HCC and identify prognosis-associated RNAs. RNA-seq data were obtained from The Cancer Genome Atlas (TCGA) database. A stage I HCC-associated miRNA-lncRNA-mRNA network was constructed. Next, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment pathway analyses of ceRNA-associated DEmRNAs were performed using Database for Annotation, Visualization, and Integrated Discovery (DAVID) 6.8 and ClusterProfiler in the R package. The protein-protein interaction (PPI) network of the above mRNAs was then constructed using STRING. Finally, the association between lncRNAs and mRNAs in the ceRNA network and prognosis of patients was further analyzed. Linear regression analysis of the above lncRNAs and mRNAs associated with overall survival was performed. After a comparison between HCC and adjacent nontumor tissues, 778 lncRNAs, 1608 mRNAs, and 102 miRNAs that were abnormally expressed were identified. The ceRNA network was composed of 56 DElncRNAs, 14 DEMiRNAs, and 30 DEmRNAs. Functional analysis results showed that 30 DEmRNAs were enriched in 14 GO biological process categories and 6 KEGG categories (false discovery rate (FDR) < 0.05). A PPI network was composed of 22 nodes and 58 edges. We detected 4 DElncRNAs (BPESC1, AC061975.6, AC079341.1, and CLLU1) and 6 DEMiRNAs (CEP55, E2F1, E2F7, EZH2, G6PD, and SLC7A11) that had significant influences on the overall survival (OS) of stage I HCC patients (P < 0.05). IncRNA BPESC1 was positively correlated with mRNA CEP55 via miR-424, and IncRNA AC061975.6 was positively correlated with mRNA E2F1 via miR-519d. Our study identified novel lncRNAs and mRNAs that were associated with the progression and prognosis of stage I HCC and further investigated the regulatory mechanism of lncRNA-mediated ceRNAs in the development of stage I HCC.

1. Introduction

Hepatocellular carcinoma (HCC) is the 6th most common cancer in the world and is the 4th leading cause of cancer-related death [1]. Cirrhosis, chronic hepatitis B and C virus infection, dietary aflatoxin exposure, and alcoholism are the most common risk factors for HCC [2, 3]. Although the diagnostic methods and surgical treatment measures for HCC continue to improve, the 5-year survival rate of late-stage HCC patients is still very low [4]. Many clinical treatments for tumors are performed based on the tumor-node-metastasis (TNM) staging system of the American Joint Committee on Cancer (AJCC) [5]. Early AJCC stage I HCC patients are most likely to be cured through treatment methods that include radiofrequency ablation (RFA), surgical resection, or liver transplantation [6].
Stage I HCC patients with 1 single tumor that has no vascular invasion have higher survival rates than do HCC patients in other stages [7]. However, the treatment effect on early HCC is still not high, and many patients eventually die from tumor recurrence and liver failure [8]. The 5-year survival rate of stage I HCC is still only approximately 50% and is greatly lower than that of stage I cancers in other organs [9]. The molecular mechanism for mediating the recurrence of early-stage HCC is still not clear. Therefore, identifying biomarkers that can accurately and reliably predict HCC prognosis in the early stage of HCC is urgently needed in order to understand the molecular mechanism underlying the poor survival period of early-stage HCC.

The relationship among long noncoding RNAs (lncRNAs), microRNAs (miRNAs), and messenger RNAs (mRNAs) is complicated. In 2011, Salmena et al. [10] proposed the hypothesis of competing endogenous RNAs (ceRNAs). The ceRNA hypothesis considers that lncRNAs not only can directly participate in the regulation of target gene expression but also may contain some core seed sequences that can adsorb corresponding miRNAs to further interfere with target genes mRNA abundance by influencing the number of miRNAs, thus affecting gene expression. Martini et al. [11] showed that the expression levels of Inc-SERTAD2-3, Inc-SOX4-1, IncHRCT1-1, and PVTV in stage I epithelial ovarian cancer (EOC) were independent prognostic markers associated with recurrence and poor prognosis. Based on an analysis of The Cancer Genome Atlas (TCGA) database, RNA sequencing, and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) experiments, Tian et al. [12] showed that 8 out of 12 candidate lncRNAs (LINC00963, NR2F2-AS1, LINC00515, LINC00162, LINC00312, MGC27382, LINC00472, and FENDRR) were significantly upregulated in stage I lung adenocarcinoma (LUAD) tissues. Ma et al. [13] showed that the lncRNA PAPAS could promote HCC through an interaction with miR-188-5p. The plasma level of PAPAS could effectively differentiate between stage I HCC patients and healthy controls. However, no study has targeted the regulatory mechanism underlying lncRNA-mediated ceRNAs in early-stage (stage I) HCC and the diagnostic and prognostic values of genes in the ceRNA network that participate in stage I HCC.

Recent studies have shown that Bai et al. constructed an HCC-associated deregulated ceRNA network consisting of 37 lncRNAs, 10 miRNAs, and 26 mRNAs after excluding lncRNAs that were localized only in the nucleus [14]. In our study, we investigated the RNA expression conditions in 171 cases (172 cases of miRNAs) of stage I HCC and 50 cases of nontumor normal liver tissues based on TCGA data. We constructed a ceRNA network containing 56 lncRNAs, 14 miRNAs, and 30 mRNAs in stage I HCC. Next, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment and protein-protein interaction (PPI) analyses were performed to elucidate the underlying mechanism. Finally, the prognostic values of the above lncRNAs, miRNAs, and mRNAs involved in the ceRNA network for determining the overall survival (OS) of stage I HCC patients were analyzed. We believe that our study might provide novel prognostic biomarkers for survival prediction and targeted treatment of early-stage HCC.

2. Materials and Methods

2.1. Data Acquisition and Selection. The gdc-client tool was used to download raw sequencing data of HCC-associated mRNA and miRNA expression from the TCGA database (https://portal.gdc.cancer.gov/). Complete clinical data of the corresponding patients were further downloaded from the cbioPortal (http://www.cbioportal.org/) website. Liver tissue specimens of stage I HCC patients (171 cases for miRNAs and lncRNAs and 172 cases for miRNAs) and 50 specimens from normal individuals were selected. The corresponding mRNA-seq, lncRNA-seq, and miRNA-seq data were further obtained. We then used the R package of edgeR to homogenize the TCGA raw data using the trimmed mean of M-values (TMM) method. If there were multiple data points for RNA expression, the average expression value was regarded as the expression value of the corresponding gene. Finally, the RNA expression level was converted to a log2 value. Our study entirely followed the publication guidelines of TCGA (https://cancergenome.nih.gov/publications/publicationguidelines); therefore, approval from an ethics committee was not required.

2.2. Identification of Differentially Expressed (DE) RNAs. Based on the annotation of the Ensembl database (http://www.ensembl.org/index.html), DElncRNAs and DEMRNAs were defined and encoded. mRNAs, IncRNAs, and miRNAs differentially expressed in stage I HCC and normal liver tissues were screened using the edgeR R package (version: 3.22.5) in R software (version 3.5.2). Statistical significance was defined as log2 fold change \( > 2 \) and a \( P \) value \( < 0.01 \). Volcano plots and heatmaps of DERNA were plotted using the ggplots and heatmap packages.

2.3. Construction of the lncRNA-miRNA-mRNA ceRNA Network. Using the miRcode database (http://www.mircode.org/), miRNAs that interacted with DElncRNAs were searched. The obtained miRNAs were modified using the StarBase database (http://starbase.sysu.edu.cn/). To further study lncRNA functions, the Perl program (version: 5.26.1) was used to predict miRNA target genes using 3 databases: miRDB (http://www.mirdb.org/), TargetScan (http://www.targetscan.org/), and miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/php/index.php). The intersecting mRNAs obtained using the 3 prediction methods were retained. The intersection between these miRNAs and DEMRNAs was then obtained using the VennDiagram R package (version: 1.6.20). DEMRNAs that were involved in the construction of the ceRNA network were obtained. The lncRNA-miRNA-mRNA ceRNA network based on the “ceRNA hypothesis” was constructed and visualized using Cytoscape v3.7.1.
2.4. Functional Enrichment Analysis. To understand the underlying biological mechanism of DEmRNAs in the ceRNA crosstalk network, the Database for Annotation, Visualization, and Integrated Discovery (DAVID) bioinformatics database (https://david-d.ncifcrf.gov/) was used to execute GO biological enrichment analyses. The ClusterProfiler v3.12.0 package of R [15] was used to analyze KEGG pathways. The GOplot package of R was used to display the results of the GO and KEGG analyses. False discovery rate (FDR) < 0.05 was set as the cut-off standard.

2.5. Construction of the PPI Network. The STRING database (version 11.0, https://string-db.org/) is a public data source that can provide information regarding the interaction between known proteins and predicted proteins. To elucidate the potential protein-protein relationship between DEmRNAs involved in the ceRNA network, a PPI network was constructed using STRING. Interactions with confidence scores above 0.4 were considered significant and were retained. Genes with a number of connections ≥ 5 were considered hub genes in the PPI network.

2.6. Survival Analysis. The association between RNAs and survival time was analyzed using Kaplan–Meier (KM) curves and the log-rank test. The survival package and ggplot2 package in R language were used for statistical analyses and plotting. \( P < 0.05 \) was set as the cut-off value.

3. Results

3.1. Differentially Expressed mRNAs, lncRNAs, and miRNAs. Detailed clinical information of the included patients is shown in Table 1. Differentially expressed (DE) mRNAs and DElncRNAs were identified when comparing 171 stage I HCC tissues and 50 normal liver tissues. A total of 1608 DEmRNAs were identified, of which 1385 mRNAs were upregulated and 223 mRNAs were downregulated. In addition, a total of 778 DElncRNAs were identified, of which 722 lncRNAs were upregulated and 56 lncRNAs were downregulated. Furthermore, a total of 102 DEmiRNAs (98 upregulated genes and 4 downregulated genes) were identified when comparing 172 stage I hepatocellular carcinoma (HCC) tissues and 50 normal liver tissues. The volcano plots of the mRNAs, lncRNAs, and miRNAs are shown in Figures 1(a)–1(c), respectively; their heatmaps are shown in Figures 1(d)–1(f), respectively.

3.2. Construction of the Competing Endogenous RNAs (ceRNAs) Network for Stage I HCC. To further investigate how lncRNAs mediated mRNAs regulation through interactions with miRNAs in stage I HCC, a lncRNA-miRNA-mRNA (ceRNA) network based on the above data was constructed and visualized using Cytoscape v3.7.1. First, we used the alignment file of the miRcode database to align DElncRNAs and miRNAs. Next, we extracted the pairs of miRNAs that interact with DElncRNAs to obtain the DElncRNA alignment file in the miRcode database. Finally, we aligned the obtained alignment results with DEmiRNAs and obtained a total of 212 pairs with successful alignment records; that is, 212 interacting lncRNA and miRNA pairs were identified from DElncRNAs and DEmiRNAs. Among these 212 interaction pairs, there were 56 lncRNAs and 14 miRNAs. We then searched for the target mRNAs of these 14 miRNAs using the miRTarBase, miRDB, and TargetScan databases and obtained a total of 718 target mRNAs. We intersected these 718 genes with the original 1608 DEmRNAs and obtained 30 DEmRNAs as nodes of the ceRNA network (Figure 2(a)). Combining the miRNA-mRNA interactions and lncRNA-miRNA interactions, a lncRNA-miRNA-mRNA network was constructed. This network was composed of 56 DElncRNAs, 14 DEmiRNAs, and 30 DEmRNAs (Figure 2(b)).

3.3. Functional Analysis of ceRNA Network-Associated DEmRNAs. Functional analysis results showed that 30 DEmRNAs in the above ceRNA network were enriched in 14 Gene Ontology (GO) biological process categories and 6 Kyoto Encyclopedia of Genes and Genomes (KEGG) categories (false discovery rate (FDR) < 0.05). The results are shown in Tables 2 and 3. The top 10 GO terms were cell cycle, regulation of cell cycle, the developmental process involved in reproduction, reproductive process, reproduction, regulation of cell cycle process, cell cycle process, regulation of nitrogen compound metabolic process, mitotic cell cycle process, and transcription factor complex (Figure 3(a)). Figure 3(b) shows the significantly enriched pathways for these DEmRNAs after KEGG pathway enrichment analyses: cell cycle, cellular senescence, p53 signaling pathway, oocyte meiosis, ferroptosis, and glutathione metabolism.

3.4. Protein-Protein Interaction (PPI) Network of ceRNA Network-Associated DEmRNAs. A PPI network was constructed using STRING and was composed of 22 nodes and 58 edges (Figure 4(a)). According to this network, there were a total of 12 hub genes (degree ≥ 5). These major hub genes included EZH2, CCNB1, RRM2, KIF23, PBK, CEP55, E2F7, CCNE1, E2F1, CLSPN, E2F2, and POLQ (Figure 4(b)). The gene with the highest degree (degree = 13) was enhancer of zeste homolog 2 (EZH2) (Figure 4(b)).

3.5. Overall Survival (OS)-Associated lncRNAs and mRNAs in the ceRNA Network. To elucidate the association between DElncRNAs in ceRNAs and the prognosis of HCC patients, KM curve analyses were performed. The results showed that 4 out of 56 DElncRNAs were significantly associated with OS (\( P < 0.05 \)). BPESC1 negatively correlated with patient OS, whereas highly expressed AC061975.6, AC079341.1, and CLLU1 significantly prolonged the survival time of patients with stage I HCC (Figures 5(a)–5(d)). Next, we performed KM curve analyses on 30 DEmRNAs in ceRNAs to study the association between DEmRNAs and the OS of patients with stage I HCC. The results suggested that 6 DEmRNAs were significantly associated with OS. These 6 DEmRNAs...
(CEP55, E2F1, E2F7, EZH2, G6PD, and SLC7A11) negatively correlated with OS (Figures 6(a)–6(e)). No significant differences were observed between DEmiRNAs and the OS of patients with stage I HCC. Details of DEmiRNAs and DElncRNAs associated with overall survival are shown in Table 4. Linear regression analysis of the 4 lncRNAs and 6 mRNAs associated with overall survival was performed. 11 lncRNA-mRNA pairs are positively correlated (Figures 7(a)–7(k), $P < 0.05$). Next, we explored whether shared miRNAs existed between the lncRNAs and mRNAs. We found that lncRNA BPESC1 was positively correlated with mRNA CEP55 through miRNA miR-424, and lncRNA AC061975.6 was positively correlated with mRNA E2F1 through miRNA miR-519d. Figure 8 shows a flow diagram of the bioinformatics analysis.

### Table 1: Clinical characteristics of the included patients.

| Characteristics                     | Number of sample size, $n = 171$ (%) (mRNA, lncRNA) | Number of sample size, $n = 172$ (%) (miRNA) |
|-------------------------------------|------------------------------------------------------|----------------------------------------------|
| **Age (years)**                     |                                                      |                                              |
| $\geq 60$                           | 95 (55.56)                                           | 95 (55.23)                                   |
| $< 60$                              | 76 (44.44)                                           | 77 (44.77)                                   |
| **Gender**                          |                                                      |                                              |
| Female                              | 50 (29.24)                                           | 49 (28.49)                                   |
| Male                                | 121 (70.76)                                          | 123 (71.51)                                  |
| **Family history**                  |                                                      |                                              |
| Yes                                 | 52 (30.41)                                           | 51 (29.65)                                   |
| No                                  | 119 (69.59)                                          | 121 (70.35)                                  |
| **Race**                            |                                                      |                                              |
| White                               | 78 (45.61)                                           | 77 (44.77)                                   |
| Asian                               | 81 (47.37)                                           | 81 (47.09)                                   |
| Black or African american           | 8 (4.68)                                             | 8 (4.65)                                     |
| NA                                  | 4 (2.34)                                             | 6 (3.49)                                     |
| **Tumor status**                    |                                                      |                                              |
| With tumor                          | 44 (25.73)                                           | 46 (26.74)                                   |
| Tumor free                          | 117 (68.42)                                          | 116 (67.44)                                  |
| NA                                  | 10 (5.85)                                            | 10 (5.81)                                    |
| **Hepatitis B virus infection**     |                                                      |                                              |
| Yes                                 | 69 (40.35)                                           | 70 (40.70)                                   |
| No                                  | 96 (56.14)                                           | 96 (55.81)                                   |
| NA                                  | 6 (3.51)                                             | 6 (3.49)                                     |
| **Histologic grade**                |                                                      |                                              |
| Grade 1                             | 25 (14.62)                                           | 25 (14.53)                                   |
| Grade 2                             | 80 (46.78)                                           | 80 (46.51)                                   |
| Grade 3                             | 55 (32.16)                                           | 56 (32.56)                                   |
| Grade 4                             | 10 (5.85)                                            | 11 (6.40)                                    |
| NA                                  | 1 (0.58)                                             | 0 (0.00)                                     |
| **Vascular invasion**               |                                                      |                                              |
| Macro                               | 5 (2.92)                                             | 5 (2.91)                                     |
| Micro                               | 17 (9.94)                                            | 18 (10.47)                                   |
| None                                | 137 (80.12)                                          | 138 (80.23)                                  |
| NA                                  | 12 (7.02)                                            | 11 (6.40)                                    |
| **Residual tumor**                  |                                                      |                                              |
| R0                                  | 154 (90.06)                                          | 155 (90.12)                                  |
| R1                                  | 5 (2.92)                                             | 5 (2.91)                                     |
| R2                                  | 0 (0.00)                                             | 0 (0.00)                                     |
| RX                                  | 9 (5.26)                                             | 9 (5.23)                                     |
| NA                                  | 3 (1.75)                                             | 3 (1.74)                                     |
| **Vital status**                    |                                                      |                                              |
| Living                              | 129 (75.44)                                          | 131 (76.16)                                  |
| Deceased                            | 42 (24.56)                                           | 41 (23.84)                                   |
| **Relapse**                         |                                                      |                                              |
| Yes                                 | 62 (36.26)                                           | 65 (37.79)                                   |
| No                                  | 88 (51.46)                                           | 88 (51.16)                                   |
| NA                                  | 21 (12.28)                                           | 19 (11.05)                                   |

### 4. Discussion

During disease diagnosis, the progression level of cancer is the key factor defining treatment methods and
Figure 1: Continued.
Figure 1: Specific lncRNA-related ceRNA network and characteristics of the constituent lncRNAs in stage I HCC patients. The volcano plot shows the expression profiles of mRNAs (a), lncRNAs (b), and miRNAs (c). Red dots indicate upregulated RNAs, and green dots indicate downregulated RNAs. Heatmaps of differentially expressed RNAs in different samples: (d) mRNAs, (e) lncRNAs, and (f) miRNAs. The y-axis represents RNAs and the x-axis represents patient samples; red denotes upregulation and green denotes downregulation. ceRNA: competing endogenous RNA; HCC: hepatocellular carcinoma; lncRNA: long noncoding RNA; miRNA: microRNA.

Figure 2: Continued.

(a) 1578
Diff
30
Target
688
Figure 2: The ceRNAs network in stage I HCC patients. (a) Venn diagram of DEmRNAs involved in the ceRNA network. (b) The ceRNA network of IncRNAs-miRNAs-mRNAs involved in HCC. Diamonds represent IncRNAs, round rectangles represent miRNAs, and triangles represent mRNAs. The nodes highlighted in red and blue indicate up- and downregulation, respectively. DEmRNA: differentially expressed mRNA.

Table 2: The top 10 GO terms enrichment for DEmRNAs involved in the ceRNA network using the DAVID database.

| GO ID     | Term                                  | Genes                                                                 | Gene count | FDR   |
|-----------|----------------------------------------|-----------------------------------------------------------------------|------------|-------|
| GO:0007049| Cell cycle                             | KIF23, E2F1, CLSPN, E2F2, PTGS2, E2F7, EZH2, PBK, CEP55, DACH1, CCNB1, CCNE1, SFRP1, RRM2, AXIN2 | 15          | 0.000 |
| GO:0051726| Regulation of cell cycle               | KIF23, CCNB1, E2F1, CLSPN, CCNE1, E2F2, PTGS2, SFRP1, E2F7, EZH2, DACH1, AXIN2 | 12          | 0.001 |
| GO:0003006| Developmental process involved in reproduction | CCNB1, PLAG1, PTGS2, SFRP1, E2F7, FOXF2, HOXA10, HOXA9, CBX2, DACH1 | 10          | 0.001 |
| GO:0022414| Reproductive process                   | E2F1, CCNB1, PLAG1, PROK2, SFRP1, PTGS2, E2F7, FOXF2, HOXA10, HOXA9, CBX2, DACH1, ACSSL4 | 13          | 0.002 |
| GO:0000003| Reproduction                            | E2F1, CCNB1, PLAG1, PROK2, SFRP1, PTGS2, E2F7, FOXF2, HOXA10, HOXA9, CBX2, DACH1, ACSSL4 | 13          | 0.002 |
| GO:0010564| Regulation of cell cycle process        | KIF23, CCNB1, E2F1, CLSPN, SFRP1, E2F7, EZH2, DACH1, AXIN2            | 9           | 0.010 |
| GO:0022402| Cell cycle process                     | KIF23, CCNB1, E2F1, CLSPN, CCNE1, E2F7, RRM2, EZH2, PBK, DACH1, CEP55, AXIN2 | 12          | 0.015 |
| GO:0051171| Regulation of nitrogen compound metabolic process | E2F1, PLAG1, E2F2, PTGS2, CPEB3, E2F7, EZH2, ELAVL2, CBX2, DACH1, CCNB1, CCNE1, HOXA3, SFRP1, RRM2, FOXF2, HOXA10, HOXA9, AXIN2, POLQ | 20          | 0.020 |
| GO:1903047| Mitotic cell cycle process             | KIF23, CCNB1, E2F1, CLSPN, CCNE1, E2F7, RRM2, EZH2, PBK, CEP55, DACH1 | 10          | 0.022 |
| GO:0005667| Transcription factor complex           | E2F1, E2F2, E2F7, FOXF2, HOXA10, HOXA9, DACH1                        | 7           | 0.023 |

Note: FDR < 0.05. GO: Gene Ontology; DEmRNAs: differentially expressed mRNA; ceRNA: competing endogenous RNA; DAVID: Database for Annotation, Visualization, and Integrated Discovery; FDR: False discovery rates.
evaluating successful treatment results. Therefore, the elucidation of molecular mechanisms in different progression stages of HCC is urgently needed. In recent years, with the advance of studies on the complicated interaction among different RNA types and RNA crosstalk in the gene regulation network, miRNAs and their ceRNA targets have been confirmed; for example, lncRNAs and mRNAs can form a complicated ceRNA network [16]. Different studies have constructed ceRNA networks with DERNAs in HCC and normal tissues based on next-generation sequencing or microarray data [17–19]. However, comprehensive analysis of ceRNA networks based on differential expression profile data for stage I HCC is lacking. Discovery and diagnosis of early-stage HCC are very critical for HCC treatment; therefore, identifying novel therapeutic targets and prognostic markers in stage I is particularly important.

In this study, we identified 778 lncRNAs, 1608 mRNAs, and 102 miRNAs that were abnormally expressed in HCC tissue based on RNA-seq data in the TCGA database. We then constructed a stage I HCC-associated miRNA-lncRNA-mRNA network. The results indicated that crosstalk among these RNAs might be an important feature of stage I HCC. Notably, among the 6 mRNAs identified in the miRNA-lncRNA-mRNA network that were associated with prognosis, E2F1 and E2F7 both belong to the E2F transcription factor family; the E2F family plays an important role in the regulation of cell cycle [20]. The results of our GO and KEGG analyses also suggested that the 6 mRNAs were mainly enriched in cell cycle pathways, including the cell cycle process and regulation of transcription involved in G1/S transition of mitotic cell cycle.

Table 3: KEGG pathway analysis for DEmRNAs involved in the ceRNA network using the ClusterProfiler package of R.

| KEGG ID   | Pathway name          | Genes             | Gene count | FDR   |
|-----------|-----------------------|-------------------|------------|-------|
| hsa04110  | Cell cycle            | CCNB1, CCNE1, E2F1, E2F2 | 4          | 0.004 |
| hsa04218  | Cellular senescence   | CCNB1, CCNE1, E2F1, E2F2 | 4          | 0.005 |
| hsa04115  | p53 signaling pathway | CCNB1, CCNE1, RRM2 | 3          | 0.005 |
| hsa04114  | Oocyte meiosis        | CCNB1, CCNE1, cpeb3 | 3          | 0.019 |
| hsa04216  | Ferroptosis           | ACSL4, SLC7A11    | 2          | 0.020 |
| hsa00480  | Glutathione metabolism| G6PD, RRM2        | 2          | 0.032 |

Note: FDR < 0.05. KEGG: Kyoto Encyclopedia of Genes and Genomes.

Figure 3: Enrichment analysis of DEmRNAs involved in the ceRNA network. (a) The top 10 significantly enriched pathways identified in the DEmRNA GO enrichment analysis. (b) Significantly enriched KEGG pathways of DEmRNAs (FDR < 0.05). GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; FDR: false discovery rate.
Figure 4: Identification of hub genes from the PPI network. (a) The PPI network of ceRNA network-associated DEMRNAs. (b) Information about nodes in the PPI network. PPI: protein-protein interaction.

Figure 5: Continued.
Figure 5: Kaplan–Meier survival curves of 4 DElncRNAs involved in the ceRNA network associated with overall survival in patients with stage I HCC ($P < 0.05$). DElncRNA: differentially expressed IncRNA.

Figure 6: Kaplan–Meier survival curves of 6 DEmRNAs involved in the ceRNA network associated with overall survival in patients with stage I HCC ($P < 0.05$).
cycle, regulation of the cell cycle, and cell cycle processes. CEP55, EZH2, and SLCA11 are highly expressed in HCC and play critical regulatory roles in cancers [21–23]. They were key nodes that made up the stage I HCC ceRNA network in our study and were key potential prognostic genes in stage I HCC, results that are consistent with a Gene Expression Omnibus (GEO) database study by Yue et al. [24]. It is notable that the above genes exhibited high degrees in the PPI network constructed using the ceRNA network-associated DEmRNAs and were major hub genes. These results suggested that they played very important roles in the biological processes of stage I HCC.

Abnormal IncRNA expression is involved in various human tumors including HCC. In recent years, intensive studies have been carried out on IncRNAs. The involvement of IncRNAs in the mechanisms of many cancers has been explored, and the same IncRNA can regulate many types of cancers at the same time. In our study on ceRNA network-associated IncRNAs, AC061975.6, AC079341.1, BPESC1, and CLLU1 were associated with the OS of stage I HCC patients. Buhl et al. [25] showed that CLLU1 was significantly upregulated in CLL cells and that the OS of CLL patients was associated with the CLLU1 expression level. When the expression level of CLLU1 increased 1-fold, the risk of early death increased by 7%. CLLU1 expression had a stronger prognostic meaning in patients younger than 70 years of age, whereas it did not have prognostic meaning in patients 70 years of age or older [26]. Cahill et al. [27] showed that high levels of DNA methylation in the CLLU1 gene were present in immunoglobulin heavy chain- (IGHV-) mutated (IGHV-M) CLL and in normal B cells of IGHV-unmutated (IGHV-UM) patients. High CLLU1 expression and the presence of the IGHV-UM gene were associated with poor clinical results [25, 28]. Yue et al. [24] used the GEO database to construct a ceRNA regulatory network of HCC. CLLU1 was a key candidate IncRNA. It was upregulated in HCC tissues and was significantly associated with the prognosis of HCC patients.

Wang et al. [29] collected microarray data sets of 26 triple-negative breast cancer (TNBC) patients who received neoadjuvant chemotherapy (NAC). Receiver operating characteristic (ROC) analyses were performed on DEIncRNAs to evaluate their predictive value in pathological complete response to NAC. The results suggested that BPESC1 was a marker with better prediction value.
However, the function of BPESC1 has not been studied in HCC and other tumors, and thus, an investigation should be performed. In addition, there is little known about the other 2 potential prognostic lncRNAs (AC061975.6 and AC079341.1). Therefore, the functions of these potential prognostic lncRNAs in HCC and other cancers should be further studied and elucidated. Although there is currently no direct evidence of their involvement in tumor development, we found that BPESC1, AC061975.6, and AC079341.1 were associated with the prognosis of patients with stage I HCC.

In addition, Bai et al. [14] used the TCGA database to construct a ceRNA regulatory network of HCC in a recent study. The KM curve analysis showed that 15 lncRNAs, 3 miRNAs, and 16 mRNAs at the nodes of the constructed ceRNA network for HCC were significantly related to the overall survival rate for HCC patients. In particular, for these overall survival-related RNAs, high expression levels of the lncRNA BPESC1 and the 5 mRNAs CEP55, E2F1, EZH2, E2F7, and SLC7A11 were related to short survival time, and the expression level of CLLU1 was positively correlated with overall survival. These findings are consistent with our conclusions. Our results indicated that the lncRNAs AC061975.6 and AC079341.1 and the mRNA G6PD were related to the overall survival, whereas these RNAs were not detected by Bai et al., this discrepancy may be mainly attributable to the construction of different ceRNA networks for HCC with different clinical characteristics.

### Table 4: The list of DEmRNAs and DElncRNAs involved in the ceRNA network associated with overall survival in patients with stage I HCC.

| Names  | Genes    | Regulation | logFC |
|--------|----------|------------|-------|
| CEP55  | mRNA     | Up         | 2.567 |
| E2F1   | mRNA     | Up         | 3.502 |
| E2F7   | mRNA     | Up         | 3.124 |
| EZH2   | mRNA     | Up         | 2.240 |
| G6PD   | mRNA     | Up         | 2.180 |
| SLC7A11| mRNA     | Up         | 4.165 |
| AC061975.6| lncRNA | Up         | 3.587 |
| AC079341.1| lncRNA | Up         | 3.097 |
| CLLU1  | lncRNA   | Up         | 3.610 |
| BPESC1 | lncRNA   | Up         | 2.876 |

In summary, through the analyses of related stage I HCC data obtained from the TCGA database, the expression profiles of lncRNAs, miRNAs, and mRNAs were obtained. A lncRNA-miRNA-mRNA ceRNA network was successfully constructed. Six DEmRNAs and 4 DElncRNAs involved in the ceRNA network that had prognostic value were identified. BPESC1 was positively correlated with mRNA CEP55 via miR-424, and AC061975.6 was positively correlated with mRNA E2F1 via miR-519d. Some of these have been reported as promising biomarkers for diagnosis and prognosis.

### 5. Conclusions

In summary, through the analyses of related stage I HCC data obtained from the TCGA database, the expression profiles of lncRNAs, miRNAs, and mRNAs were obtained. A lncRNA-miRNA-mRNA ceRNA network was successfully constructed. Six DEmRNAs and 4 DElncRNAs involved in the ceRNA network that had prognostic value were identified. BPESC1 was positively correlated with mRNA CEP55 via miR-424, and AC061975.6 was positively correlated with mRNA E2F1 via miR-519d. Some of these have been reported as promising biomarkers for diagnosis and prognosis.
Data Availability
The data used to support the findings of this study are included within the article.

Disclosure
This research was performed as part of the employment of the authors (the Second Hospital of Nanjing, Medical School, Southeast University).

Conflicts of Interest
There are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions
Xuefeng Gu and Hongbo Li contributed equally to this work.

References
[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[2] K. Schütte, J. Bornschein, and P. Malfertheiner, "Hepatocellular carcinoma—epidemiological trends and risk factors," Digestive Diseases, vol. 27, no. 2, pp. 80–92, 2009.
[3] H. Nordenstedt, D. White, and H. El-Serag, "The changing pattern of epidemiology in hepatocellular carcinoma," Digestive and Liver Disease, vol. 42, no. 3, pp. S206–S214, 2010.
[4] J. Bruix and M. Sherman, "Management of hepatocellular carcinoma: an update," Hepatology, vol. 53, no. 3, pp. 1020–1022, 2011.
[5] S. B. Edge and C. C. Compton, "The American Joint Committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM," Annals of Surgical Oncology, vol. 17, no. 6, pp. 1471–1474, 2010.
[6] J.-H. Wang, C.-C. Wang, C.-H. Hung, C.-L. Chen, and S.-N. Lu, "Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma," Journal of Hepatology, vol. 56, no. 2, pp. 412–418, 2012.
[7] N. Shimosawa and K. Hanazaki, "Longterm prognosis after hepatic resection for small hepatocellular carcinoma," Journal of the American College of Surgeons, vol. 198, no. 3, pp. 356–365, 2004.
[8] J. M. Llovet, A. Burroughs, and J. Bruix, "Hepatocellular carcinoma," The Lancet, vol. 362, no. 9399, pp. 1907–1917, 2003.
[9] S. Edge, D. Byrd, C. Compton et al., AJCC Cancer Staging Manual, Springer, New York, NY, USA, 2010.
[10] L. Salmena, L. Poliseno, Y. Tay, L. Kats, and P. P. Pandolfi, "A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?" Cell, vol. 146, no. 3, pp. 353–358, 2011.
[11] P. Martini, L. Paracchini, G. Caratti et al., "LncRNAs as novel indicators of patients’ prognosis in stage I epithelial ovarian cancer: a retrospective and multicentric study," Clinical Cancer Research, vol. 23, no. 9, pp. 2356–2366, 2017.
[12] Z. Tian, S. Wen, Y. Zhang et al., "Identification of dysregulated long non-coding RNAs/microRNAs/miRNAs in TNM I stage lung adenocarcinoma," Oncotarget, vol. 8, no. 31, pp. 31703–31718, 2017.
[13] J. Ma, C. Qin, Z. Yuan, and S. Liu, "LncRNA PAPAS promotes hepatocellular carcinoma by interacting with miR-188-5p," Journal of Cellular Biochemistry, vol. 120, no. 8, pp. 13494–13500, 2019.
[14] Y. Bai, J. Long, Z. Liu et al., "Comprehensive analysis of a ceRNA network reveals potential prognostic cytoplasmic lncRNAs involved in HCC progression," Journal of Cellular Physiology, vol. 234, no. 10, pp. 18837–18848, 2019.
[15] G. Yu, L.-G. Wang, Y. Han, and Q.-Y. He, "ClusterProfiler: an R package for comparing biological themes among gene clusters," OMICS: A Journal of Integrative Biology, vol. 16, no. 5, pp. 284–287, 2012.
[16] Y. Tay, J. Rinn, and P. P. Pandolfi, "The multilayered complexity of ceRNA crosstalk and competition," Nature, vol. 505, no. 7483, pp. 344–352, 2014.
[17] J. Zhang, D. Fan, Z. Jian, G. G. Chen, and P. B. Lai, "Cancer specific long noncoding RNAs show differential expression patterns and competing endogenous RNA potential in hepatocellular carcinoma," PLoS One, vol. 10, no. 10, Article ID e0141042, 2015.
[18] P. Lin, D. Wen, Q. Li et al., "Genome-wide analysis of prognostic IncRNAs, miRNAs, and mRNAs forming a competing endogenous RNA network in hepatocellular carcinoma," Cellular Physiology and Biochemistry, vol. 48, no. 5, pp. 1953–1967, 2018.
[19] J. Long, Y. Bai, X. Yang et al., "Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma," Cancer Cell International, vol. 19, no. 1, p. 90, 2019.
[20] L. di Stefano, M. R. Jensen, and K. Helin, "E2F7, a novel E2F family member, is a repressor of the p16INK4a promoter," EMBO Journal, vol. 22, no. 23, pp. 6289–6298, 2003.
[21] S. Hajós-Kalcakosz, K. Dezső, E. Bugyik et al., "Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors," Diagnostic Pathology, vol. 7, no. 1, p. 86, 2012.
[22] M. Li, J. Gao, D. Li, and Y. Yin, "CEP55 promotes cell motility via JAK2(-)STAT3(-)MMPs cascade in hepatocellular carcinoma," Cells, vol. 7, no. 8, p. 99, 2018.
[23] L. Zhang, Y. Huang, J. Jing et al., "Overexpression of SLC7A11: a novel oncogene and an indicator of unfavorable prognosis for liver carcinoma," Future Oncology, vol. 14, no. 10, pp. 927–936, 2018.
[24] C. Yue, Y. Ren, H. Ge et al., "Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma," OncoTargets and Therapy, vol. 12, pp. 561–576, 2019.
[25] A. M. Buhl, J. Jurlander, C. H. Geisler et al., "CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia," European Journal of Haematology, vol. 76, no. 6, pp. 455–464, 2006.
[26] P. Joselsson, C. H. Geisler, H. Leffers et al., "CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia," Blood, vol. 109, no. 11, pp. 4973–4979, 2007.
[27] N. Cahill, A.-C. Bergh, M. Kanduri et al., "450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in...
resting and proliferative compartments,” *Leukemia*, vol. 27, no. 1, pp. 150–158, 2013.

[28] M. Mansouri, M. Sevov, E. Fahlgren et al., "Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity," *Leukemia Research*, vol. 34, no. 3, pp. 301–306, 2010.

[29] Q. Wang, C. Li, P. Tang, R. Ji, S. Chen, and J. Wen, "A minimal lincRNA-mRNA signature predicts sensitivity to neoadjuvant chemotherapy in triple-negative breast cancer," *Cellular Physiology and Biochemistry*, vol. 48, no. 6, pp. 2539–2548, 2018.